期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

丙型肝炎抗病毒新药研究进展 被引量：4

暂未订购
导出
摘要 全球约1／3人群感染丙型肝炎病毒（HCV）。HCV感染是慢性肝炎、肝硬化和肝衰竭的主要病因之一，慢性丙型肝炎的有效治疗方法在全球均是紧迫的医疗难题之一。相当多的慢性丙型肝炎患者，特别是基因1、4型HCV感染者、原发无应答者、
作者 何秋鸿 金生
机构地区 阆中市人民医院感染科 重庆医科大学附属第二医院 重庆医科大学病毒性肝炎研究所
出处 《现代医药卫生》 2013年第24期3722-3726,共5页 Journal of Modern Medicine & Health
关键词 肝炎 丙型 药物疗法 RNA 病毒 干扰素类 治疗应用 抗病毒药 治疗应用 利巴韦林 综述
分类号 R512.63 [医药卫生—内科学]
  • 相关文献

参考文献35

  • 1Cernescu C, Ruta S, Gheorghe L, et al. The flying publisher guide to hepatitis C treatment[M/OL]. Bemd Kamps Steinh~iuser Verlag 2011 : 58-7812013-08-01].http ://scripts.sil.org/OFL.
  • 2Gonzalez SA, Keeffe EB. Management of chronic hepatitis C treat- ment failures : role of consensus interferon[J]. Biologics, 2009,3 : 141-150.
  • 3Sjogren MH, Sjogren R, Hohzmuller K, et al. Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treat- ment of chronic hepatitis C[J]. Dig Dis Sci, 2005,50 (4) : 727-732.
  • 4Leevy CB. Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated inter- feron alfa-2b and ribavirin[J]. Dig Dis Sci ,2008,53 (7):1961- 1966.
  • 5Bacon BR, Shiffman ML, Mendes F, et al. Retreating chronic he- patitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin : DIRECT results[J]. Hepatology, 2009,49(6) : 1838-1846.
  • 6Meyer DF,Tobias H, Min AD, et al. Retreatment of patients non-responsive to pegylated interferon and ribavirin with daily high- dose consensus interferon[J]. Hepat Res Treat, 2010,2010: 537827.
  • 7Kishida Y, Imaizumi N, Tanimura H, et al. Restoration of innate and adaptive immune responses by HCV viral inhibition with an induction approach using natural interferon-beta in chronic hep- atitis C[J]. Clin Dev Immunol, 2012,2012 : 582716.
  • 8Arase Y, Suzuki Y, Suzuki F, et al. Efficacy of reduction therapy of natural human ~-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load[J]. He- patol Res, 2012,42(8) :750-756.
  • 9Arase Y ,Kawamura Y ,Suzuki Y ,et al. Efficacy of reduction therapy of natural human 13-interferon and ribavirin in elderly patients with chronic hepatitis C ,genotype lb and high viral load[J]. He- patol Res,2012,42(10) :949-957.
  • 10Couzigou P, P6msat S, Bourli~re M, et al. Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patientsI / with chronic hepatitis C (ANRS HC16 GAMMATRI)[J]. J Gast / troenterol Hepatol, 2013,28 (2) : 329-334. |.

同被引文献44

  • 1Andrew Lee,Jeremy Rajanayagam,Mona Abdel-Hady.Chronic Hepatitis C Infection in Children: Current Treatment and New Therapies[J].Journal of Clinical and Translational Hepatology,2015,3(1):36-41. 被引量：2
  • 2Mortada Hassan El-Shabrawi,Naglaa Mohamed Kamal Alanani.Burden of pediatric hepatitis C[J].World Journal of Gastroenterology,2013,19(44):7880-7888. 被引量：11
  • 3中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南[S].2005-12-10.
  • 4姜娟.干扰素的用药教育与用药实践分析[C].2013年中国临床药学学术年会暨第九届临床药师论坛论文集.2013.
  • 5陈红.聚乙二醇化重组集成干扰素在丙型肝炎受试者中耐受性和早期疗效分析[D].长春:吉林大学,2013.
  • 6Marcelo S,Jorge P,Cutler D,et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa - 2b in patients with chronic hepatitis C [J]. J Hepatol, 2006,45 : 204-213.
  • 7Jenny H,Bressler B,Wang B,et al. Pharmakokinetics and response of obese patients with chronic hepatitis C treat- ed with different doses of PEG - IFNot 2a (40KD) (Pe- gasys) [J]. Br J Clin Pharmacol,2009,67:280-287.
  • 8Danish F A, Koul S S, Subhani F R, et al. Antiviral therapy in HCV-infected decompensated cirrhotics [ J 1.SaudiJGastroenterol,2010,16(4):310-314.
  • 9魏来主编.丙型肝炎临床诊断及治疗[M].北京:科学出版社,2012:77.
  • 10Janicko M, Veseltny E, Lesko D, et al. Serum cholester- ol is a significant and independent mortality predictor in liver cirrhosis patients [ J ]. Ann Hepatol, 2013,12 ( 4 ) : 581-587.

引证文献4

二级引证文献12

现代医药卫生
2013年 第24期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部